InvestorsHub Logo
Followers 37
Posts 6485
Boards Moderated 3
Alias Born 05/06/2014

Re: None

Wednesday, 02/14/2024 8:08:30 AM

Wednesday, February 14, 2024 8:08:30 AM

Post# of 642
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
02/14/2024

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission

Link:
https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTXR News